TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

TScan Therapeutics (NASDAQ:TCRX) announced its quarterly earnings results on Wednesday. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02), Zacks reports. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

TScan Therapeutics Price Performance

Shares of NASDAQ TCRX opened at $1.92 on Thursday. The firm has a market cap of $102.47 million, a P/E ratio of -1.81 and a beta of 0.87. The business’s 50 day moving average is $2.45 and its 200-day moving average is $4.06. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a 1-year low of $1.82 and a 1-year high of $9.69.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Thursday. Needham & Company LLC reduced their price objective on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Wedbush reiterated an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Wednesday.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.